Exosomes in acute myeloid leukemia inhibit hematopoiesis

Current Opinion in Hematology
Michael Boyiadzis, Theresa L Whiteside

Abstract

Exosomes are cell-derived, biologically active membrane-bound vesicles, and are emerging as key modulators of hematopoiesis. Recent studies have provided a clearer understanding of the mechanisms whereby blast-derived exosomes act to suppress hematopoiesis in acute myeloid leukemia (AML). Exosomes released from leukemia blasts have been shown to suppress hematopoietic progenitor cell (HPC) functions indirectly through stromal reprogramming of niche-retention factors and also as a consequence of AML exosome-directed microRNA delivery to HPC. Furthermore, exosomes secreted by AML blasts remodel the bone marrow niche into a leukemia growth-permissive microenvironment. Exosomes suppress hematopoiesis in AML. Strategies to block the production, secretion and reprogramming that exosomes induce may be a novel therapeutic approach in AML and other leukemias.

References

Aug 21, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Eva U WieckowskiTheresa L Whiteside
Nov 15, 2012·Cancer Research·Jianya HuanPeter Kurre
May 17, 2013·The Journal of Clinical Investigation·Ye ChenMichael Andreeff
Aug 1, 2013·Proceedings of the National Academy of Sciences of the United States of America·Farideh Miraki-MoudDavid C Taussig
May 2, 2014·Frontiers in Immunology·Chang-Sook HongMichael Boyiadzis
Jun 25, 2014·Current Opinion in Cell Biology·Joanna KowalClotilde Théry
Feb 18, 2015·Blood Reviews·Michael Boyiadzis, Theresa L Whiteside
Sep 17, 2015·The New England Journal of Medicine·Hartmut DöhnerClara D Bloomfield
Feb 13, 2016·Current Opinion in Hematology·Junko H OhyashikiKazuma Ohyashiki
Apr 2, 2016·The Journal of Clinical Investigation·Paul D RobbinsCori N Booker
Apr 5, 2016·Expert Review of Molecular Diagnostics·Michael Boyiadzis, Theresa L Whiteside
Mar 23, 2017·Leukemia·M Boyiadzis, T L Whiteside

❮ Previous
Next ❯

Citations

Dec 14, 2018·International Journal of Molecular Sciences·Enrico Pierluigi SpugniniStefano Fais
Mar 3, 2020·Frontiers in Bioengineering and Biotechnology·Xuewu ZhangWenjuan Yu
Dec 6, 2019·Frontiers in Oncology·Nur' Syahada Ab RazakNadiah Abu
Oct 30, 2020·International Journal of Nanomedicine·Victor C Kok, Cheng-Chia Yu
Jul 23, 2021·Cell Biology International·Maedeh MasoumipourSeyed Hadi Mousavi
Nov 19, 2021·International Journal of Oncology·Mohammed Awal IssahJianzhen Shen

❮ Previous
Next ❯

Methods Mentioned

BETA
xenografts
xenograft

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.